Abbott Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Abbott's estimated annual revenue is currently $42.3B per year.(i)
  • Abbott's estimated revenue per employee is $248,890
  • Abbott's current valuation is $226.6B. (January 2022)

Employee Data

  • Abbott has 169995 Employees.(i)
  • Abbott grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1488.1M148078%N/AN/A
#2
$69340M1073104%N/A$308.4B
#3
$55170M566975%$10.9M$240.2B
#4
$42310M1699955%N/A$226.6B
#5
$16.1M801%N/AN/A
Add Company

Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries.

keywords:N/A

N/A

Total Funding

169995

Number of Employees

$42.3B

Revenue (est)

5%

Employee Growth %

$226.6B

Valuation

N/A

Accelerator

Abbott's People

NameTitleEmail/Phone
1
EVP, VenturesReveal Email/Phone
2
Director, Business Human Resources, VascularReveal Email/Phone
3
Regional Director - Enterprise AccountsReveal Email/Phone
4
Assoc. Director Regional / Govt. MarketingReveal Email/Phone
5
Sr Program ManagerReveal Email/Phone
6
Director, North America Quality OperationsReveal Email/Phone
7
Senior IT ManagerReveal Email/Phone
8
Supplier Realtionship ManagerReveal Email/Phone
9
Div. VP R&D - CRMReveal Email/Phone
10
Director, BenefitsReveal Email/Phone

Abbott News

2022-04-20 - What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the...

2022-04-20 - What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the...